BCG::ESX-1Mmar is a recombinant BCG strain into which the extended region of the ESX-1-encoding genomic region of Mycobacterium marinum was integrated.
Sponsor / Lead Developer: Institut Pasteur Paris
Primary Indication: Prevention of TB disease
Other Indication(s): Prevention of Mtb infection or sustained infection, Prevention of TB disease, and Prevention of TB recurrence
Target Population(s): Adolescents, Adults, Children, and Infants
Target Route of Administration: Intradermal
Immune tissue localization: Lung and Lymph node
Immunological responses: T-cell
Preclinical Animal Models: Guinea pig and Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
|T-cell functional profile
Induction of cytosolic immune signalling
|Preferential immune tissue localization
The vaccine candidate is used in the framework of the EU-supported TBVAC-Horizon project.